Nationwide Fund Advisors Buys Shares of 53,100 Kadmon Holdings Inc (KDMN)
Nationwide Fund Advisors purchased a new stake in shares of Kadmon Holdings Inc (NASDAQ:KDMN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 53,100 shares of the company’s stock, valued at approximately $192,000. Nationwide Fund Advisors owned 0.10% of Kadmon Holdings as of its most recent SEC filing.
Separately, Macquarie Group Ltd. acquired a new position in Kadmon Holdings during the fourth quarter worth approximately $2,696,000.
Kadmon Holdings Inc (NASDAQ:KDMN) traded down 0.8933% during midday trading on Friday, hitting $2.2299. The stock had a trading volume of 225,211 shares. The company’s market capitalization is $115.61 million. Kadmon Holdings Inc has a 52 week low of $2.21 and a 52 week high of $10.48. The company’s 50-day moving average price is $3.21 and its 200 day moving average price is $3.28.
Kadmon Holdings (NASDAQ:KDMN) last announced its earnings results on Thursday, August 3rd. The company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.05. The business had revenue of $3 million for the quarter, compared to the consensus estimate of $3.46 million. During the same period in the prior year, the business posted ($4.40) EPS. Kadmon Holdings’s revenue for the quarter was down 53.1% on a year-over-year basis. On average, analysts expect that Kadmon Holdings Inc will post ($1.65) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/04/nationwide-fund-advisors-acquires-shares-of-53100-kadmon-holdings-inc-kdmn-updated-updated-updated.html.
A number of research firms have commented on KDMN. Piper Jaffray Companies set a $7.00 price objective on Kadmon Holdings and gave the stock a “buy” rating in a research note on Wednesday. ValuEngine lowered Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Zacks Investment Research downgraded Kadmon Holdings from a “buy” rating to a “hold” rating and set a $4.25 target price for the company. in a research report on Tuesday, June 27th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Kadmon Holdings in a research report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $9.93.
In related news, major shareholder Goldentree Asset Management Lp sold 515,643 shares of the firm’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $3.51, for a total transaction of $1,809,906.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 1,840,331 shares of company stock valued at $6,193,607 in the last three months.
About Kadmon Holdings
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Stock Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related stocks with our FREE daily email newsletter.